Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ERAS-601 + sotorasib
- Development stage
- Discontinued
- Lead developer
- Erasca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ERAS-601 + sotorasib is an investigational **oral combination therapy** for cancer. ERAS-601 is a potent, selective, and orally bioavailable allosteric inhibitor of SHP2, a phosphatase that transduces receptor tyrosine kinase signaling to the RAS/MAPK pathway, inhibiting RAS signaling[3]. Sotorasib is an approved, selective, oral small molecule inhibitor targeting the KRAS G12C mutation, a common oncogenic driver in several cancers, notably non-small cell lung cancer (NSCLC)[2][6]. The rationale for combining these agents is to target multiple nodes of the RAS/MAPK pathway for enhanced antitumor activity, particularly in cancers harboring KRAS G12C mutations. Preclinical and early-phase clinical data support this combination in patients with advanced cancers such as NSCLC[3][5][7].
- Other names
- ERAS-601 + sotorasib
02
Targets
KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)
Beyond the preview
Go deeper on ERAS-601 + sotorasib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ERAS-601 + sotorasib.